H.C. Wainwright analyst Douglas Tsao reiterated a Buy rating on Theravance Biopharma (TBPH – Research Report) today and set a price target of $20.00.
Douglas Tsao has given his Buy rating due to a combination of factors that point towards the growth and resilience of Theravance Biopharma’s product portfolio and financial prospects. Tsao is encouraged by the continuing strong performance of Yupelri, a treatment for COPD, despite setbacks from a cyberattack on a healthcare partner. The product has shown significant year-over-year revenue growth and has captured a larger share of the long-acting nebulized COPD market. The expectation of regulatory advancement in China and associated milestone payments, along with high-performing royalties from the drug Trelegy, further contribute to a positive outlook for Theravance.
Additionally, the potential of ampreloxetine, which is being developed for symptomatic neurogenic orthostatic hypotension in multiple system atrophy patients, cannot be ignored. Despite a setback in broader Phase 3 studies, the drug showed a strong benefit in a subset of patients, indicating a promising future with orphan drug pricing and significant market penetration. Tsao’s analysis suggests that investors may be underestimating this opportunity, and with the company’s push towards non-GAAP break-even in the near future, the financial health of Theravance seems strong.
TipRanks tracks over 100,000 company insiders, identifying the select few who excel in timing their transactions. By upgrading to TipRanks Premium, you will gain access to this exclusive data and discover crucial insights to guide your investment decisions. Begin your TipRanks Premium journey today.
Theravance Biopharma (TBPH) Company Description:
Theravance Biopharma, Inc. operates as a biopharmaceutical company. It focuses on the discovery, research, development, and commercialization of organ-selective medicines. Its products include telavancin under the VIBATIV brand, revefenacin under the TD 4208 brand, and neprilysin. The company was founded in July 2013 and is headquartered in George Town, Cayman Islands.
